News

These Stocks Are Moving the Most Today: Tesla, Domino’s, Nvidia, Merck, Spirit AeroSystems, Meta, and More
Domino’s Pizza reports earnings, Nvidia faces stiff competition in China, and Spirit AeroSystems finalizes a deal to transfer ...
Merck KGaA to buy Springworks for $3.9 billion
Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...
Merck Faces Patent Lawsuit Over Easier-to-Use Keytruda
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
Merck Cuts 2025 Outlook on Tariffs, Charges
Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...
Halozyme sues Merck; FDA blames cuts for Vanda delay
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
Devdiscourse22h
Global Health Updates: From Mergers to Measles and Medicine
The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...
The American Journal of Managed Care19h
Pembrolizumab Before, After Surgery Improves Head and Neck Cancer Outcomes: Ravindra Uppaluri, MD, PhD
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5% ...